CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 158 filers reported holding CLOVIS ONCOLOGY INC in Q4 2021. The put-call ratio across all filers is 1.47 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $56,000 | -34.1% | 46,952 | -0.0% | 0.00% | – |
Q2 2022 | $85,000 | -71.8% | 46,960 | -68.4% | 0.00% | – |
Q1 2022 | $301,000 | -12.2% | 148,714 | +17.1% | 0.00% | – |
Q4 2021 | $343,000 | -36.0% | 127,041 | +6.0% | 0.00% | – |
Q3 2021 | $536,000 | -16.6% | 119,831 | +7.9% | 0.00% | – |
Q2 2021 | $643,000 | -29.1% | 111,085 | -14.1% | 0.00% | – |
Q1 2021 | $907,000 | -55.0% | 129,291 | -69.2% | 0.00% | -100.0% |
Q4 2020 | $2,016,000 | -23.4% | 420,188 | -6.9% | 0.00% | -50.0% |
Q3 2020 | $2,631,000 | -24.7% | 451,300 | -12.8% | 0.00% | 0.0% |
Q2 2020 | $3,492,000 | +267.2% | 517,324 | +246.2% | 0.00% | +100.0% |
Q1 2020 | $951,000 | -60.0% | 149,437 | -34.5% | 0.00% | 0.0% |
Q4 2019 | $2,378,000 | +182.1% | 228,056 | +6.5% | 0.00% | 0.0% |
Q3 2019 | $843,000 | -80.8% | 214,134 | -27.4% | 0.00% | -75.0% |
Q2 2019 | $4,388,000 | -59.5% | 295,075 | -32.4% | 0.00% | -60.0% |
Q1 2019 | $10,842,000 | +166.1% | 436,794 | +92.5% | 0.01% | +150.0% |
Q4 2018 | $4,074,000 | -54.5% | 226,872 | -25.6% | 0.00% | -50.0% |
Q3 2018 | $8,958,000 | -3.9% | 304,945 | +48.7% | 0.01% | -11.1% |
Q2 2018 | $9,322,000 | -23.9% | 205,006 | -11.6% | 0.01% | -18.2% |
Q1 2018 | $12,249,000 | +92.7% | 232,009 | +148.3% | 0.01% | +83.3% |
Q4 2017 | $6,355,000 | -59.4% | 93,451 | -50.8% | 0.01% | -60.0% |
Q3 2017 | $15,650,000 | +4.0% | 189,931 | +18.2% | 0.02% | 0.0% |
Q2 2017 | $15,042,000 | -10.4% | 160,653 | -39.1% | 0.02% | 0.0% |
Q1 2017 | $16,796,000 | +180.1% | 263,809 | +95.4% | 0.02% | +150.0% |
Q4 2016 | $5,996,000 | -57.2% | 134,988 | -65.3% | 0.01% | -53.8% |
Q3 2016 | $14,008,000 | +732.8% | 388,578 | +216.7% | 0.01% | +550.0% |
Q2 2016 | $1,682,000 | -43.4% | 122,697 | -20.7% | 0.00% | -50.0% |
Q1 2016 | $2,971,000 | -32.1% | 154,786 | +23.8% | 0.00% | -20.0% |
Q4 2015 | $4,375,000 | -54.6% | 125,000 | +19.3% | 0.01% | -58.3% |
Q3 2015 | $9,635,000 | -21.9% | 104,781 | -25.4% | 0.01% | 0.0% |
Q2 2015 | $12,341,000 | +10.5% | 140,427 | -6.7% | 0.01% | +9.1% |
Q1 2015 | $11,173,000 | +54.0% | 150,509 | +16.2% | 0.01% | +83.3% |
Q4 2014 | $7,253,000 | +26.3% | 129,533 | +2.3% | 0.01% | +20.0% |
Q3 2014 | $5,743,000 | +12.7% | 126,581 | +2.9% | 0.01% | +25.0% |
Q2 2014 | $5,094,000 | +1.8% | 123,018 | +70.2% | 0.00% | -20.0% |
Q1 2014 | $5,006,000 | +15.9% | 72,289 | +0.9% | 0.01% | +25.0% |
Q4 2013 | $4,318,000 | -3.1% | 71,654 | -2.2% | 0.00% | 0.0% |
Q3 2013 | $4,454,000 | +406.7% | 73,251 | +457.8% | 0.00% | +300.0% |
Q2 2013 | $879,000 | – | 13,131 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |